The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?
By Irv Arons and Mark Hillen
Enjoyed what you have read so far? Sign up for free to read the rest! Log in or sign up to read this article in full and to gain access The Ophthalmologist entire content archive.
or sign in with:
Sign up now